Eric J. Ende - 14 Nov 2022 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
Director
Signature
/s/ Keith A. Kucinski, attorney-in fact for Eric Ende,
Issuer symbol
MTNB
Transactions as of
14 Nov 2022
Transactions value $
$0
Form type
4
Filing time
16 Nov 2022, 20:33:19 UTC
Previous filing
12 Sep 2022
Next filing
23 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Stock option (right to buy) Award $0 +142,657 $0.000000 142,657 14 Nov 2022 Common Stock 142,657 $0.7268 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.